Chronic methamphetamine exposure alters immune function in normal and retrovirus-infected mice

Qianli Yu, Dongqin Zhang, Michael Walston, Jin Zhang, Yingyin Liu, Ronald R Watson

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Methamphetamine (MA) abuse represents a growing problem in the USA with an increase of sudden death. To evaluate the immune function alterations due to chronic methamphetamine use, we examined C57BL/C mice with LP-BM5 retrovirus infection plus methamphetamine exposure. Mice were randomly assigned to the following groups: placebo, placebo retrovirus-infected, uninfected MA treated and retrovirus-infected MA treated. Placebo, MA-treated groups were intraperitoneally injected with saline, MA, respectively, with a gradually increasing dose from 15 to 40 mg/kg for 12 weeks (5 days/week). Con A- and LPS-induced mitogenesis of splenocytes, cytokine production by splenocytes culture and lipid peroxides in the liver were measured. Heart tissue histopathology was analyzed in all the groups with murine cytomegalovirus (CMV) superinfection. Our data showed that MA treatment significantly decreased production of IL-2 and interferon gamma (IFN-γ) in uninfected mice but did not further suppress the reduced Th1 cytokines in retrovirus-infected mice. There were no significant effects on cytokines IL-4 and IL-6. However, tumor necrosis factor (TNF-α) was significantly increased in both uninfected and infected mice due to MA treatment. Lipid peroxides in liver were significantly increased both in uninfected and retrovirus-infected mice due to MA exposure. Vitamin E levels in liver were significantly decreased in uninfected mice due to MA treatment. CMV superinfection greatly increased the cardiac lesions in retrovirus-infected mice while no significant histopathology changes were detected due to MA treatment. Our data suggest that MA has immunomodulation activity, suppressing Th1 cytokine production and enhancing some Th2 cytokine secretion, as well as increasing lipid peroxides in uninfected mice. The interaction between LP-BM5 and MA remains unclear.

Original languageEnglish (US)
Pages (from-to)951-962
Number of pages12
JournalInternational Immunopharmacology
Volume2
Issue number7
DOIs
StatePublished - 2002

Fingerprint

Methamphetamine
Retroviridae
Cytokines
Lipid Peroxides
Superinfection
Placebos
Liver
Retroviridae Infections
Muromegalovirus
Immunomodulation
Therapeutics
Sudden Death
Cytomegalovirus
Vitamin E
Inbred C57BL Mouse
Interleukin-4
Interferon-gamma
Interleukin-2
Interleukin-6

Keywords

  • Cytokine
  • Immune function
  • LP-BM5 murine leukemia
  • Methamphetamine
  • Murine AIDS

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

Chronic methamphetamine exposure alters immune function in normal and retrovirus-infected mice. / Yu, Qianli; Zhang, Dongqin; Walston, Michael; Zhang, Jin; Liu, Yingyin; Watson, Ronald R.

In: International Immunopharmacology, Vol. 2, No. 7, 2002, p. 951-962.

Research output: Contribution to journalArticle

Yu, Qianli ; Zhang, Dongqin ; Walston, Michael ; Zhang, Jin ; Liu, Yingyin ; Watson, Ronald R. / Chronic methamphetamine exposure alters immune function in normal and retrovirus-infected mice. In: International Immunopharmacology. 2002 ; Vol. 2, No. 7. pp. 951-962.
@article{9ced6d153a7841dda40bda72cf427f80,
title = "Chronic methamphetamine exposure alters immune function in normal and retrovirus-infected mice",
abstract = "Methamphetamine (MA) abuse represents a growing problem in the USA with an increase of sudden death. To evaluate the immune function alterations due to chronic methamphetamine use, we examined C57BL/C mice with LP-BM5 retrovirus infection plus methamphetamine exposure. Mice were randomly assigned to the following groups: placebo, placebo retrovirus-infected, uninfected MA treated and retrovirus-infected MA treated. Placebo, MA-treated groups were intraperitoneally injected with saline, MA, respectively, with a gradually increasing dose from 15 to 40 mg/kg for 12 weeks (5 days/week). Con A- and LPS-induced mitogenesis of splenocytes, cytokine production by splenocytes culture and lipid peroxides in the liver were measured. Heart tissue histopathology was analyzed in all the groups with murine cytomegalovirus (CMV) superinfection. Our data showed that MA treatment significantly decreased production of IL-2 and interferon gamma (IFN-γ) in uninfected mice but did not further suppress the reduced Th1 cytokines in retrovirus-infected mice. There were no significant effects on cytokines IL-4 and IL-6. However, tumor necrosis factor (TNF-α) was significantly increased in both uninfected and infected mice due to MA treatment. Lipid peroxides in liver were significantly increased both in uninfected and retrovirus-infected mice due to MA exposure. Vitamin E levels in liver were significantly decreased in uninfected mice due to MA treatment. CMV superinfection greatly increased the cardiac lesions in retrovirus-infected mice while no significant histopathology changes were detected due to MA treatment. Our data suggest that MA has immunomodulation activity, suppressing Th1 cytokine production and enhancing some Th2 cytokine secretion, as well as increasing lipid peroxides in uninfected mice. The interaction between LP-BM5 and MA remains unclear.",
keywords = "Cytokine, Immune function, LP-BM5 murine leukemia, Methamphetamine, Murine AIDS",
author = "Qianli Yu and Dongqin Zhang and Michael Walston and Jin Zhang and Yingyin Liu and Watson, {Ronald R}",
year = "2002",
doi = "10.1016/S1567-5769(02)00047-4",
language = "English (US)",
volume = "2",
pages = "951--962",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "7",

}

TY - JOUR

T1 - Chronic methamphetamine exposure alters immune function in normal and retrovirus-infected mice

AU - Yu, Qianli

AU - Zhang, Dongqin

AU - Walston, Michael

AU - Zhang, Jin

AU - Liu, Yingyin

AU - Watson, Ronald R

PY - 2002

Y1 - 2002

N2 - Methamphetamine (MA) abuse represents a growing problem in the USA with an increase of sudden death. To evaluate the immune function alterations due to chronic methamphetamine use, we examined C57BL/C mice with LP-BM5 retrovirus infection plus methamphetamine exposure. Mice were randomly assigned to the following groups: placebo, placebo retrovirus-infected, uninfected MA treated and retrovirus-infected MA treated. Placebo, MA-treated groups were intraperitoneally injected with saline, MA, respectively, with a gradually increasing dose from 15 to 40 mg/kg for 12 weeks (5 days/week). Con A- and LPS-induced mitogenesis of splenocytes, cytokine production by splenocytes culture and lipid peroxides in the liver were measured. Heart tissue histopathology was analyzed in all the groups with murine cytomegalovirus (CMV) superinfection. Our data showed that MA treatment significantly decreased production of IL-2 and interferon gamma (IFN-γ) in uninfected mice but did not further suppress the reduced Th1 cytokines in retrovirus-infected mice. There were no significant effects on cytokines IL-4 and IL-6. However, tumor necrosis factor (TNF-α) was significantly increased in both uninfected and infected mice due to MA treatment. Lipid peroxides in liver were significantly increased both in uninfected and retrovirus-infected mice due to MA exposure. Vitamin E levels in liver were significantly decreased in uninfected mice due to MA treatment. CMV superinfection greatly increased the cardiac lesions in retrovirus-infected mice while no significant histopathology changes were detected due to MA treatment. Our data suggest that MA has immunomodulation activity, suppressing Th1 cytokine production and enhancing some Th2 cytokine secretion, as well as increasing lipid peroxides in uninfected mice. The interaction between LP-BM5 and MA remains unclear.

AB - Methamphetamine (MA) abuse represents a growing problem in the USA with an increase of sudden death. To evaluate the immune function alterations due to chronic methamphetamine use, we examined C57BL/C mice with LP-BM5 retrovirus infection plus methamphetamine exposure. Mice were randomly assigned to the following groups: placebo, placebo retrovirus-infected, uninfected MA treated and retrovirus-infected MA treated. Placebo, MA-treated groups were intraperitoneally injected with saline, MA, respectively, with a gradually increasing dose from 15 to 40 mg/kg for 12 weeks (5 days/week). Con A- and LPS-induced mitogenesis of splenocytes, cytokine production by splenocytes culture and lipid peroxides in the liver were measured. Heart tissue histopathology was analyzed in all the groups with murine cytomegalovirus (CMV) superinfection. Our data showed that MA treatment significantly decreased production of IL-2 and interferon gamma (IFN-γ) in uninfected mice but did not further suppress the reduced Th1 cytokines in retrovirus-infected mice. There were no significant effects on cytokines IL-4 and IL-6. However, tumor necrosis factor (TNF-α) was significantly increased in both uninfected and infected mice due to MA treatment. Lipid peroxides in liver were significantly increased both in uninfected and retrovirus-infected mice due to MA exposure. Vitamin E levels in liver were significantly decreased in uninfected mice due to MA treatment. CMV superinfection greatly increased the cardiac lesions in retrovirus-infected mice while no significant histopathology changes were detected due to MA treatment. Our data suggest that MA has immunomodulation activity, suppressing Th1 cytokine production and enhancing some Th2 cytokine secretion, as well as increasing lipid peroxides in uninfected mice. The interaction between LP-BM5 and MA remains unclear.

KW - Cytokine

KW - Immune function

KW - LP-BM5 murine leukemia

KW - Methamphetamine

KW - Murine AIDS

UR - http://www.scopus.com/inward/record.url?scp=0036317842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036317842&partnerID=8YFLogxK

U2 - 10.1016/S1567-5769(02)00047-4

DO - 10.1016/S1567-5769(02)00047-4

M3 - Article

C2 - 12188036

AN - SCOPUS:0036317842

VL - 2

SP - 951

EP - 962

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 7

ER -